Pre-clinical evidence of FGF21’s potential role in metabolism includes resistance to diet induced obesity in mice overexpressing FGF21 (Kharitonenkov et al., 2005) and improved glucose tolerance in obese mice through administration of recombinant FGF21 (Kharitonenkov et al., 2005). The gene discussed is FGF21; the disease is obesity disorder.